May 5, 2020
Pfizer, BioNTech in first doses in U.S. in global COVID-19 vaccine making
First participants have been dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: COVID-19
May 5, 2020
Athersys enrolls patients testing MultiStem cell therapy for COVID-19 induced ARDS
Athersys started enrollment of patients testing MultiStem cell therapy in a rapid advancement of clinical program for the treatment of ARDS based on prior clinical data reflecting favorable tolerability data and meaningful benefits on mortality, ventilator-free days and ICU-days
May 4, 2020
Milken Institute sees over 100 vaccines and near 200 treatments in development (COVID-19)
The Milken Institute COVID-19 Treatment and Vaccine Tracker has identified more than 111 vaccines and 197 treatments in the pipeline to treat and prevent COVID-19.
May 4, 2020
Why Pharma product launch strategy really matters for businesses?
During the COVID-19 crisis, it is critical for companies in the pharmaceutical market to take calculative and well-executed measures to ensure business continuity in the long run.
May 4, 2020
Arcturus Therapeutics, Catalent to make COVID-19 vaccine
Arcturus Therapeutics and Catalent have entered a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to protect against the SARS-CoV-2 coronavirus.
May 2, 2020
Gilead’s investigational COV-19 treatment Remdesivir gets FDA’s emergency use authorization
Gilead get’s authorization of emergency use of Remdesivir to treat hospitalized patients with severe COVID-19 disease in the United States.
May 1, 2020
Moderna, Lonza work on Moderna’s Corona Vaccine
Moderna has engaged with Lonza to work on its novel coronavirus vaccine, with a goal to enable manufacturing of up to 1 billion doses per year, noting that technology transfer is expected to begin in June 2020.
May 1, 2020
Shionogi expecting Fetcroja available in coming weeks
Shionogis’ Fetcroja (cefiderocol) in the end of April 2020 received European Commission (EC) marketing authorisation for the treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options.
May 1, 2020
Athersys and University Hospitals Cleveland Medical Center Announce Activation of the First Clinical Site for the MACOVIA Study, a Pivotal Phase 2/3 Study Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS
University Hospitals Cleveland Medical Center, a nationally ranked hospital, is ready to start screening patients CLEVELAND–(BUSINESS WIRE)–$ATHX #ARDS–Athersys, Inc. (NASDAQ:…
April 30, 2020
Nicoya support researchers during COVID-19
Nicoya, a leading provider of advanced analytical instruments for the biotechnology and pharmaceutical industries, announced today that they will be offering Surface Plasmon Resonance (SPR) technical support to all researchers – at no cost – during COVID-19.